Analysts’ Recent Ratings Changes for Insmed (INSM)

A number of research firms have changed their ratings and price targets for Insmed (NASDAQ: INSM):

• 9/30/2026 – Insmed had its price target lowered by Barclays PLC from $237.00 to $207.00. They now have an “overweight” rating on the stock.
• 9/24/2026 – Insmed is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $188.00 price target on the stock.
• 9/24/2026 – Insmed is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $188.00 price target on the stock.
• 9/15/2026 – Insmed had its “buy” rating reaffirmed by Roth Capital. They now have a $198.00 price target on the stock, down from $212.00.
• 8/10/2026 – Insmed had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $195.00 price target on the stock, up from $185.00.
• 8/10/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright.
• 8/10/2026 – Insmed had its price target lowered by JPMorgan Chase & Co. from $179.00 to $175.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Insmed had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $218.00 price target on the stock.
• 8/7/2026 – Insmed had its “outperform” rating reaffirmed by Evercore Inc. They now have a $170.00 price target on the stock.
• 8/7/2026 – Insmed had its price target lowered by Guggenheim from $207.00 to $205.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Insmed had its “buy” rating reaffirmed by UBS Group AG. They now have a $172.00 price target on the stock.
• 8/7/2026 – Insmed had its price target raised by Wells Fargo & Company from $161.00 to $169.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Insmed had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $175.00 price target on the stock.

Insider Activity

In other news, Director David Brennan sold 25,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director owned 39,238 shares of the company’s stock, valued at $4,865,512. This trade represents a 38.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total value of $1,256,062.60. Following the transaction, the chief executive officer owned 259,058 shares in the company, valued at approximately $30,413,409.20. This trade represents a 3.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 275,549 shares of company stock worth $36,320,872. Insiders own 2.10% of the company’s stock.

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.